Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus

Background: Platelets from patients with diabetes mellitus are hyperactive. Hyperactivated platelets may contribute to cardiovascular complications and inadequate responses to antiplatelet agents in the setting of diabetes mellitus. However, the underlying mechanism of hyperactivated platelets is not completely understood. Methods: We measured P2Y12 expression on platelets from patients with type 2 diabetes mellitus and on platelets from rats with diabetes mellitus. We also assayed platelet P2Y12 activation by measuring cAMP and VASP phosphorylation. The antiplatelet and antithrombotic effects of AR-C78511 and cangrelor were compared in rats. Finally, we explored the role of the nuclear factor-&kgr;B pathway in regulating P2Y12 receptor expression in megakaryocytes. Results Platelet P2Y12 levels are 4-fold higher in patients with type 2 diabetes mellitus compared with healthy subjects. P2Y12 expression correlates with ADP-induced platelet aggregation (r=0.89, P<0.01). P2Y12 in platelets from patients with diabetes mellitus is constitutively activated. Although both AR-C78511, a potent P2Y12 inverse agonist, and cangrelor have similar antiplatelet efficacy on platelets from healthy subjects, AR-C78511 exhibits more powerful antiplatelet effects on diabetic platelets than cangrelor (aggregation ratio 36±3% versus 49±5%, respectively, P<0.05). Using a FeCl3-injury mesenteric arteriole thrombosis model in rats and an arteriovenous shunt thrombosis model in rats, we found that the inverse agonist AR-C78511 has greater antithrombotic effects on GK rats with diabetes mellitus than cangrelor (thrombus weight 4.9±0.3 mg versus 8.3±0.4 mg, respectively, P<0.01). We also found that a pathway involving high glucose-reactive oxygen species-nuclear factor-&kgr;B increases platelet P2Y12 receptor expression in diabetes mellitus. Conclusions Platelet P2Y12 receptor expression is significantly increased and the receptor is constitutively activated in patients with type 2 diabetes mellitus, which contributes to platelet hyperactivity and limits antiplatelet drug efficacy in type 2 diabetes mellitus.

[1]  D. Baltimore,et al.  30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology , 2017, Cell.

[2]  S. Mundell,et al.  Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. , 2016, Blood.

[3]  E. Barbato,et al.  Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients). , 2016, Circulation.

[4]  L. Been,et al.  Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study , 2016, Circulation.

[5]  M. Brownlee,et al.  Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes. , 2016, Circulation research.

[6]  P. Zimmet,et al.  Epidemiology of Diabetes—Status of a Pandemic and Issues Around Metabolic Surgery , 2016, Diabetes Care.

[7]  K. Gregory,et al.  Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[8]  B. Vogt,et al.  Oxidative Stress and Nuclear Factor κB (NF-κB) Increase Peritoneal Filtration and Contribute to Ascites Formation in Nephrotic Syndrome* , 2016, The Journal of Biological Chemistry.

[9]  N. Makita,et al.  Inverse agonism: the classic concept of GPCRs revisited [Review]. , 2016, Endocrine journal.

[10]  Emma L. Smith,et al.  The Regulation of NF-κB Subunits by Phosphorylation , 2016, Cells.

[11]  Mark D. Huffman,et al.  Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association , 2016, Circulation.

[12]  C. Patrono,et al.  In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes , 2015, Diabetes.

[13]  D. Reda,et al.  Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. , 2015, The New England journal of medicine.

[14]  X. Ming,et al.  A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon acutus Venom Hydrolysates , 2015, Scientific Reports.

[15]  Shenmin Zhang,et al.  Nucleotide-Binding Oligomerization Domain 2 Receptor Is Expressed in Platelets and Enhances Platelet Activation and Thrombosis , 2022 .

[16]  Sherif Hafez,et al.  Metformin Treatment in the Period After Stroke Prevents Nitrative Stress and Restores Angiogenic Signaling in the Brain in Diabetes , 2014, Diabetes.

[17]  I. Xanthopoulou,et al.  Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes , 2013, Diabetes Care.

[18]  T. Schöneberg,et al.  Identification of Determinants Required for Agonistic and Inverse Agonistic Ligand Properties at the ADP Receptor P2Y12 , 2013, Molecular Pharmacology.

[19]  S. Kunapuli,et al.  Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12 , 2012, Journal of thrombosis and haemostasis : JTH.

[20]  L. Køber,et al.  Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. , 2012, JAMA.

[21]  Xunbin Wei,et al.  BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase , 2011, Thrombosis and Haemostasis.

[22]  D. Angiolillo,et al.  Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome , 2011, Circulation.

[23]  Masafumi Ueno,et al.  Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease , 2011, Thrombosis and Haemostasis.

[24]  J. Fischer,et al.  Regulation of Functionally Active P2Y12 ADP Receptors by Thrombin in Human Smooth Muscle Cells and the Presence of P2Y12 in Carotid Artery Lesions* , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[25]  P. Light,et al.  The Third Intracellular Loop Stabilizes the Inactive State of the Neuropeptide Y1 Receptor* , 2008, Journal of Biological Chemistry.

[26]  Pier Franco Pignatti,et al.  Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease , 2007, BMC Medical Genetics.

[27]  A. IJzerman,et al.  Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. , 2006, Trends in pharmacological sciences.

[28]  J. Akkerman,et al.  Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[29]  Honglin Zhou,et al.  Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-κB activation , 2005, The Journal of experimental medicine.

[30]  S. Kunapuli,et al.  Identification of a Potent Inverse Agonist at a Constitutively Active Mutant of Human P2Y12 Receptor , 2005, Molecular Pharmacology.

[31]  E. Minar,et al.  Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y12, and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery Disease , 2005, Stroke.

[32]  S. Kunapuli,et al.  Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses. , 2004, Blood.

[33]  S. Kunapuli,et al.  Central role of the P2Y12 receptor in platelet activation. , 2004, The Journal of clinical investigation.

[34]  P. Fontana,et al.  P2Y12 H2 Haplotype Is Associated With Peripheral Arterial Disease: A Case-Control Study , 2003, Circulation.

[35]  G. Milligan.  Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. , 2003, Molecular pharmacology.

[36]  T. Schöneberg,et al.  The Structural Evolution of a P2Y-like G-protein-coupled Receptor* , 2003, Journal of Biological Chemistry.

[37]  P. Fontana,et al.  Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects , 2003, Circulation.

[38]  C. Vergin,et al.  Investigation of megakaryocyte apoptosis in children with acute and chronic idiopathic thrombocytopenic purpura , 2003, European journal of haematology.

[39]  A. Ceriello.  New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. , 2003, Diabetes care.

[40]  S. J. Huang,et al.  Induction of platelet activation by cobra venom factor from Naja naja atra in rat. , 2000, Acta pharmacologica Sinica.

[41]  A. Parfitt,et al.  Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. , 1996, The New England journal of medicine.

[42]  A. Ciechanover,et al.  Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. C. Johnson,et al.  Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Jüppner,et al.  A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. , 1995, Science.

[45]  D. Tschoepe,et al.  Evidence for abnormal platelet glycoprotein expression in diabetes mellitus , 1990, European journal of clinical investigation.

[46]  Michael J Morgan,et al.  Crosstalk of reactive oxygen species and NF-κB signaling , 2011, Cell Research.

[47]  A. Kirk,et al.  Human platelets exhibit chemotaxis using functional N-formyl peptide receptors. , 2005, Experimental hematology.

[48]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[49]  E. Lander,et al.  Genetic analysis of non-insulin dependent diabetes mellitus in the GK rat , 1996, Nature Genetics.

[50]  A. Böyum.  Separation of leukocytes from blood and bone marrow. Introduction. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.